



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018. INDIA.**
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • **CIN:** L24230MH1960PLC011586

Date: 09th August, 2025

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

BSE Scrip Code: 506260

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Sub: Newspaper Publication of Un-audited Financial Results for the quarter ended 30th June, 2025.

Dear Sir/Ma'am,

Pursuant to the Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, advertisement have been published by the company on Saturday, 09th August, 2025 in Financial Express (English) and Mumbai Lakshdeep (Marathi) Edition pertaining to Unaudited Financial Results containing a Quick Response Code and the details of the Webpage where the aforesaid complete Financial Results of the Company for the quarter ended 30th June, 2025 is accessible. Copies of said publications are enclosed for your information and record.

This disclosure is being simultaneously uploaded on the website of the company, www.anuhpharma.com

Kindly take the same on your records.

Thanking you,

Yours faithfully

FOR ANUH PHARMA LIMITED

MANAN VADHAN
COMPANY SECRETARY AND COMPLIANCE OFFICER

Encl: As above



JAYSHREE NIRMAN LTD.

Regd Office: Room No. 503, 1 British India Street, Kolkata - 700 069
 CIN No. : L45202WB1992PLC054157
 Email Id : jayshreenirmanlimited@gmail.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

Sl. No.	Particulars	STANDALONE		
		Quarter ending June 2025	Year to Date from 01/04/2025 to 30/06/2025	Previous year ending March 31, 2025
		(Unaudited)	(Unaudited)	(Audited)
Rs. in '000				
1.	Total Income from Operations (Net)	1,60,482.86	1,60,482.86	3,54,595.15
2.	Net Profit / (Loss) from ordinary activities before tax	-3,772.38	-3,772.38	67,738.22
3.	Net Profit / (Loss) from ordinary activities after tax	-3,773.46	-3,773.46	46,948.19
4.	Total Comprehensive Income for (Profit) / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	37,339.29	37,339.29	3,08,648.63
5.	Paid-up Equity Share Capital	50,612.00	50,612.00	50,612.00
	Face Value of Rs. 10 each	10.00	10.00	10.00
6.	Reserves excluding Revaluation Reserve as per Balance Sheet	31,74,830	31,74,830	31,37,490
7.	Net Worth	32,25,442	32,25,442	31,88,102
8.	Earnings Per Share (Basic & Diluted) -	-0.075	-0.075	9.28

Note:
 The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the quarterly financial results may be accessed on the Company's website at www.jayshreenirmanlimited.com.

By the Order of the Board
 For Jayshree Nirman Limited
 Sd/-
 Ankit Mahensaria
 AUTHORISED SIGNATORY
 DIN: 07334059

Date: 08/08/2025
 Place: Kolkata

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

VALIANT LABORATORIES LIMITED

Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.
 T: 022-49712001 / 49717220 / 49717221 | E: investor@valiantlabs.in | Web: www.valiantlabs.in | CIN : L24299MH2021PLC365904

STATEMENT OF STANDALONE AND CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER JUNE 30, 2025 (Rs. in lakhs except for share data)

Particulars	Standalone				Consolidated			
	Quarter ended		Year ended		Quarter ended		Year ended	
	30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
Total Income from Operations (Net)	5,167.85	5,842.39	2,105.80	13,878.99	4,747.81	5,547.10	2,169.81	13,881.68
Net Profit / (Loss) for the period before Tax	244.58	392.36	(77.19)	(144.78)	244.87	93.91	(16.20)	(151.26)
Exceptional Items	-	-	-	-	-	-	-	-
Net Profit / (Loss) for the period after Tax	181.57	323.83	(100.56)	(215.02)	182.09	70.36	(50.93)	(220.12)
Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	181.57	321.56	(100.56)	(217.28)	182.09	67.96	(50.93)	(222.52)
Paid-up Equity Share Capital	4,345.00	4,345.00	4,345.00	4,345.00	4,345.00	4,345.00	4,345.00	4,345.00
Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year	-	-	-	19,093.31	-	-	-	19,086.01
Earning per share (in ₹)								
(a) Basic	0.42	0.74	(0.23)	(0.50)	0.42	0.16	(0.12)	(0.51)
(b) Diluted	0.42	0.74	(0.23)	(0.50)	0.42	0.16	(0.12)	(0.51)

Notes:
 1) The above is an extract of detailed format of Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the websites of the Stock Exchange(s), viz., www.bseindia.com and www.nseindia.com and website of the Company on www.valiantlabs.in
 2) The above Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 8, 2025.
 3) The Financial Results have been prepared in accordance with Indian Accounting Standards ("IndAS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For and on behalf of Board of Directors
 For Valiant Laboratories Limited
 Sd/-
 Santosh Vora
 Managing Director
 DIN: 07633923

Place : Mumbai
 Date : August 8, 2025



NANDANI CREATION LIMITED

Regd. Office: G-13, Kartarpura Industrial Area, Near 22 Godam, Jaipur-302006
 Phone: 0141-4037596, CIN: L18101RJ2012PLC037976
 Web-site: www.nandanicreation.com, e-mail: info@jaipurkurti.com

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE, 2025 (Figures in Lacs except EPS)

Sr. No.	PARTICULARS	QUARTER ENDED		YEAR ENDED	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
1.	Total Income from Operations	2729.96	2030.48	1821.57	7065.87
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	98.67	61.95	179.49	495.62
3.	Net Profit/(Loss) for the period before Tax, (After Exceptional and/or Extraordinary Items)	98.67	61.95	179.49	495.62
4.	Net Profit/(Loss) for the period after Tax, (After Exceptional and/or Extraordinary Items)	70.14	46.79	133.97	357.19
5.	Total Comprehensive Income for the period	64.88	48.29	135.31	367.71
6.	Paid-up Equity Share Capital (face value of Rs. 10 each)	1909.07	1726.16	1193.40	1726.16
7.	Earnings per Share (Face Value of Rs. 10/- each) Basic & Diluted (not annualized for quarters)	0.37	0.27	1.16	2.32

Sr. No.	PARTICULARS	QUARTER ENDED		YEAR ENDED	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
1.	Total Income from Operations	2730.24	2031.20	1832.81	7080.68
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	104.32	89.01	160.74	517.43
3.	Net Profit/(Loss) for the period before Tax, (After Exceptional and/or Extraordinary Items)	104.32	89.01	160.74	517.43
4.	Net Profit/(Loss) for the period after Tax, (After Exceptional and/or Extraordinary Items)	72.08	68.41	114.45	371.09
5.	Total Comprehensive Income for the period	66.82	69.91	115.83	375.87
6.	Paid-up Equity Share Capital (face value of Rs. 10 each)	1909.07	1726.16	1193.40	1726.16
7.	Earnings per Share (Face Value of Rs. 10/- each) Basic & Diluted (not annualized for quarters)	0.38	0.40	0.99	2.41

NOTES:
 A) The results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 08th August, 2025. B) The above is an extract of the detailed format of Un-Audited Standalone and Consolidated Results for the Quarter ended 30th June, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015. The full format of the statement of Standalone and Consolidated Financial Results are available on the Company's website (www.nandanicreation.com) and on the website of the National Stock Exchange of India limited (www.nseindia.com).

For NANDANI CREATION LIMITED
 Sd/-
 ANUJ MUNDHRA
 CHAIRMAN & MANAGING DIRECTOR
 DIN: 05202504

Date: 09.08.2025
 Place: Jaipur



Namdev Finvest Private Limited

Registered Office: S1-S7-S8, Shree Nath Plaza, Second Floor, Near Sagar Market, Bhankrola, Ajmer Road, Jaipur-302026 • Tel.: 0141 2250026 • Web: <https://www.namfin.in> • Email: info@namfin.in

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 (Amount in INR Crores, except EPS)

Sl No	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Un-Audited	Un-Audited	Un-Audited	Audited
1	Total Income from Operations	90.12	89.23	75.71	330.40
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	17.57	20.58	10.17	57.95
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	17.57	20.58	10.17	57.95
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	13.02	10.83	7.39	40.58
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	12.84	7.17	7.38	37.06
6	Paid up Equity Share Capital	28.46	28.46	28.22	28.46
7	Reserves (excluding Revaluation Reserve)	437.72	423.87	389.91	423.87
8	Securities Premium Account	322.52	322.45	238.43	322.45
9	Net worth	478.37	484.51	409.45	484.51
10	Paid up Debt Capital/ Outstanding Debt	1321.04	1419.65	1162.04	1419.65
11	Outstanding Redeemable Preference Shares	NIL	NIL	NIL	NIL
12	Debt Equity Ratio	2.76	3.06	2.86	3.06
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)				
	1. Basic:	4.60	3.77	2.62	14.38
	2. Diluted:	3.27	2.81	1.84	10.26
14	Capital Redemption Reserve	Not Applicable	Not Applicable	Not Applicable	Not Applicable
15	Debture Redemption Reserve	Not Applicable	Not Applicable	Not Applicable	Not Applicable
16	Debt Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable
17	Interest Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Notes: (1) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange(s) under Regulation 52 of the LODR Regulations. The full format of the quarterly financial results are available on the websites of the Stock Exchange(s) and the listed entity, (<https://bseindia.com>) and (<https://www.namfin.in>) (2) For the other items referred in the regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange(s) (BSE Ltd.) and can be accessed on the URL, (<https://bseindia.com>). (3) The impact on net profit / loss, total comprehensive income or any other relevant financial items(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.

For and on behalf of Board of Directors of
 NAMDEV FINVEST PRIVATE LIMITED
 Sd/-
 Jitendra Tanwar (Managing Director & CEO)
 DIN: 05149836

Date : 08.08.2025
 Place : Jaipur

ANUH PHARMA LIMITED

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018.
 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600;
 Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025 (Rs. in Lakhs)

Particulars	3 months ended		3 months ended		3 months ended		12 months ended	
	30/06/2025		31/03/2025		30/06/2024		31/03/2025	
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
Total Revenue from Operation	18,647.94	19,813.95	13,790.83	16,151.49	18,647.94	19,813.95	13,790.83	16,151.49
Net Profit/(Loss) for the period before tax	1,095.31	1,727.97	1,226.64	6,100.53	1,095.31	1,727.97	1,226.64	6,100.53
Net Profit/(Loss) for the period after Tax	830.12	1,245.70	950.91	4,735.19	830.12	1,245.70	950.91	4,735.19
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	824.05	1,255.97	944.97	4,733.49	824.05	1,255.97	944.97	4,733.49
Paid up Equity Share Capital ("face value of Rs 5/- per share)	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60
Other Equity (Excluding revaluation reserve)	-	-	-	30,096.88	-	-	-	30,096.88
Earnings per equity share (For respective periods) (in Rs.)								
- Basic Rs.	1.66	2.49	1.90	9.45	1.66	2.49	1.90	9.45
- Diluted Rs.	1.66	2.49	1.90	9.45	1.66	2.49	1.90	9.45

Notes:
 1. The above is an extract of the detailed format of Financial Results for the quarter ended on 30th June 2025, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter ended on 30th June 2025 is available on the Stock Exchange website viz. www.bseindia.com and www.nseindia.com and on the Company's website i.e. www.anuhpharma.com.
 2. Other Financial Indicators (Rs. in Lakhs)

Particulars	3 months ended		3 months ended		3 months ended		12 months ended	
	30/06/2025		31/03/2025		30/06/2024		31/03/2025	
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
EBITDA	1,367.94	2,006.92	1,428.81	7,036.40	1,367.94	2,006.92	1,428.81	7,036.40
% of EBITDA Margin	7.34	10.13	10.36	10.64	7.34	10.13	10.36	10.64
EBITDA (Adjusted to Forex gain / loss and mark to market on Investment in Mutual funds)	1,143.16	2,152.09	1,250.86	6,821.55	1,143.16	2,152.09	1,250.86	6,821.55
% of Adjusted EBITDA Margin	6.13	10.85	9.07	10.31	6.13	10.85	9.07	10.31

For Anuh Pharma Ltd
 Sd/-
 Ritesh Shah
 Joint Managing Director
 (DIN: 02496729)

Place : Mumbai
 Date : 08th August, 2025



JNK INDIA LIMITED

(FORMERLY KNOWN AS JNK INDIA PRIVATE LIMITED)
 Registered Office : Unit No. 203, 204, 205 & 206, Opp. TMC Office, Centrum IT Park, Near Satkar Hotel, Thane-West, Thane - 400604, Maharashtra. CIN: L29268MH2010PLC204223. Website : www.jnkindia.com

EXTRACT OF STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		[Unaudited]	[Audited]	[Unaudited]	[Audited]
1	Revenue from operations	991.68	1,909.44	879.94	4,766.45
2	Profit before exceptional items and tax	19.81	220.68	72.63	440.62
3	Profit before tax	19.81	220.68	72.63	440.62
4	Net profit after tax	11.27	132.38	63.75	302.04
5	Net profit after tax attributable to owners of the Company	11.27	132.38	63.75	302.04
6	Total comprehensive income attributable to owners of the Company	8.94	133.87	64.67	299.19
7	Paid-up equity share capital (Face value of share INR 2 each)	111.91	111.57	111.24	111.57
8	Other equity attributable to owners of the Company	4,941.11	4,932.15	4,810.45	4,932.15
9	Earning per share (EPS)				
	Basic EPS (Rs.)	0.20	2.37	1.33	5.47
	Diluted EPS (Rs.)	0.20	2.37	1.32	5.46
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		[Unaudited]	[Audited]	[Unaudited]	[Audited]

